Navigation Links
Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Date:1/23/2008

esponses," said Steven W. King, president and CEO of Peregrine. "We are optimistic that this new trial, along with our other Phase II bavituximab breast cancer trial, will provide us with valuable insights into bavituximab's potential in this important disease. We are now proceeding with final preparations for the trial and look forward to study initiation in the near future."

Tumor response in this study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

The National Cancer Institute estimates that approximately 178,480 U.S. women were diagnosed with breast cancer in 2007 and 40,460 women died of the disease. According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. Peregrine has now received regulatory approval for three Phase II clinical trials to study the anti-tumor effects of bavituximab in combination with chemotherapy: A breast cancer protocol in combination with docetaxel, a second breast cancer protocol in combination with carboplatin plus paclitaxel, and
'/>"/>

SOURCE Peregrine Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
(Date:9/23/2014)... 23, 2014   COTA, Inc. today announced ... million Series A funding round led by Horizon Healthcare ... the first big data platform designed by practicing oncologists ... for cancer care in support of healthcare,s new value-based ... expand development of the COTA platform, hire biostatisticians, outcome ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
...  ZHUHAI, China, Oct. 24, 2011 ... a leading global manufacturer of electronic medical devices ... worldwide technology licensing agreement and the launch of ...  new generation of modular patient monitors. The agreement ...
... Mont., Oct. 24, 2011 Bacterin International ... leader in the development of revolutionary bone graft material and ... at the Singular Research,s Sixth Annual ,Best of the Uncovereds, ... Boulevard Hotel in Los Angeles, California. Bacterin,s chairman ...
Cached Medicine Technology:Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 2Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 3Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 4Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 5Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 6Bacterin to Present at Sixth Annual Singular Research 'Best of the Uncovereds' Conference on October 26, 2011 2
(Date:9/23/2014)... Sinica, the preeminent academic institution in the Republic ... agreement to develop a unique educational and scientific ... to translate innovative technologies and commercially relevant discoveries ... Sept.12 in Taipei by Harris Lewin, vice chancellor ... Wong of Academia Sinica. The program will be ...
(Date:9/23/2014)... TX (PRWEB) September 23, 2014 As ... taken before making a purchase. It’s difficult to trust ... it’s easy for them to manipulate their customers into ... this dilemma, but they tend to lack in depth ... Health Reports was founded to fix this issue ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... What information do patients need ... Forum (NQF) released a report ( http://bit.ly/1DwekE9 ), ... infographic ( http://bit.ly/1tX3lzA ) resulting from an in-depth ... patients define affordability, and what information and changes ... possible healthcare at the lowest possible cost. ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... unapproved prescription drugs is growing, so doctors need ... Food and Drug Administration warned Tuesday. In ... so widespread that it has launched a program ... and administrators about proper drug purchasing procedures. The ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Finding Affordable Care: Asking the Right Question is Key 2
... Alan Mozes HealthDay Reporter , TUESDAY, Dec. 20 ... wriggling) competition in cleaning troublesome wounds: maggots. To the ... suggests that bagging up live, sterile fly larvae in tightly ... be a quick, safe and effective way to clear ...
... Gordon HealthDay Reporter , TUESDAY, Dec. 20 (HealthDay ... a doctor should decide if complications are severe enough to ... (ADA) says. In a new position statement published in ... advises against blanket bans or restrictions. Instead, it recommends that ...
... accounts for the majority of all thyroid malignancies, which primarily ... nodes in the neck in these cancer patients may help ... thyroid cancer metastasizes, lymph nodes in the neck may be ... not be detected by ultrasounds done before surgery to remove ...
... 20 (HealthDay News) -- Increasing concentrations of two ... samples collected in the Great Lakes region between ... The chemicals are used to reduce flammability in ... and polyurethane foams. They are 2-ethylhexyl tetrabromobenzoate [TBB] ...
... 20, 2011Women who are at risk for breast cancer may ... has found. The majority of women with hereditary breast ... or BRCA2 genes, which normally suppress the growth of breast ... at St. Michael,s Hospital, said his research team was surprised ...
... HealthDay Reporter , MONDAY, Dec. 19 (HealthDay News) -- ... likely to develop inflammatory bowel disease such as Crohn,s disease ... according to a new long-term study. Endometriosis ... grows outside of the uterus. Symptoms include abdominal pain, ...
Cached Medicine News:Health News:Maggots Quickly Clean Up Wounds, Study Shows 2Health News:Maggots Quickly Clean Up Wounds, Study Shows 3Health News:Driving Isn't An Issue for Most People With Diabetes 2Health News:Driving Isn't An Issue for Most People With Diabetes 3Health News:Removal of lymph nodes during surgery for thyroid cancer may be beneficial 2Health News:Removal of lymph nodes during surgery for thyroid cancer may be beneficial 3Health News:Buildup of Newer Flame Retardants Concerns Scientists 2Health News:Breast cancer and heart disease may have common roots 2Health News:Endometriosis Tied to Higher Risk of Crohn's, Colitis 2
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Terumo's Outlook offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
Medicine Products: